TickerFacts.

Vor Biopharma Inc. (VOR): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$164.31M
As of 2025-12-31
-$200.20M
As of 2026-06-30
$250.61M2020-12-31: -$59.06M2021-12-31: $216.26M2022-12-31: $250.61M2023-12-31: $150.72M2024-12-31: $96.66M2025-12-31: -$164.31M-$164.31M
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$164.31Mn/m2026-03-30, Balance as of period end
2024-12-31$96.66M-35.9%2026-03-30, Balance as of period end
2023-12-31$150.72M-39.9%2025-03-20, Balance as of period end
2022-12-31$250.61M+15.9%2024-03-20, Balance as of period end
2021-12-31$216.26Mn/m2023-03-23, Balance as of period end
2020-12-31-$59.06Mn/a2022-03-14, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Vor Biopharma Inc. (VOR)2025-12-31-$164.31Mn/m
REGENXBIO Inc. (RGNX)2025-12-31$102.73M-60.4%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$233.06M+4.5%
Cullinan Therapeutics, Inc. (CGEM)2025-12-31$408.73M-30.8%
Vericel Corp (VCEL)2025-12-31$354.64M+21.5%
ImmunityBio, Inc. (IBRX)2025-12-31-$500.47Mn/m
Adaptive Biotechnologies Corp (ADPT)2025-12-31$218.79M+7.9%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31-$119.15Mn/m
Sana Biotechnology, Inc. (SANA)2025-12-31$160.88M-35.8%

Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗